Gosens M J E M, Dresen R C, Rutten H J T, Nieuwenhuijzen G A P, van der Laak J A W M, Martijn H, Tan-Go I, Nagtegaal I D, van den Brule A J C, van Krieken J H J M
Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands.
Ann Oncol. 2008 Dec;19(12):2026-32. doi: 10.1093/annonc/mdn428. Epub 2008 Jul 29.
Not all patients with locally advanced rectal cancer (LARC) respond equally to neo-adjuvant radiochemotherapy (RCT). Patients with highly apoptotic less advanced rectal cancers do not benefit from short-term radiotherapy. This study investigates whether this is also the case in the setting of RCT for LARC.
Tissue microarrays were constructed of biopsy and resection specimens of 201 LARC patients. Apoptosis (M30) and several apoptosis-regulating proteins [p53, Bcl-2, Bax, cyclooxygenase-2 (Cox-2) and mamma serine protease inhibitor (maspin)] were studied with immunohistochemistry. Subsequently, predictive values for local recurrence (LR), overall survival (OS) and histological tumour regression were analysed.
Apoptotic levels, quantified as the number of apoptotic cells/mm(2) tumour epithelium, were higher in posttherapy tissues compared with biopsies (P < 0.001). Biopsies from clinical T4 stage tumours demonstrated significantly higher levels of apoptosis than clinical T3 stage tumours (P = 0.020). Therapy-induced apoptosis was higher when the interval between the last day of irradiation and surgery increased (P < 0.001, correlation coefficient = 0.355). Pre- and posttherapy apoptosis, p53, Bcl-2, Bax and Cox-2 were not associated with LR, OS or tumour regression. Intense pretherapy cytoplasmatic staining of maspin indicated a higher risk on LR (P = 0.009) only.
Combined RCT is also successful in highly apoptotic tumours and is therefore independent of intrinsic apoptosis.
并非所有局部晚期直肠癌(LARC)患者对新辅助放化疗(RCT)的反应都相同。凋亡程度高、病情较轻的直肠癌患者无法从短期放疗中获益。本研究调查在LARC的RCT背景下是否也是如此。
构建了201例LARC患者的活检和切除标本的组织微阵列。采用免疫组织化学研究凋亡(M30)和几种凋亡调节蛋白[p53、Bcl-2、Bax、环氧合酶-2(Cox-2)和乳腺丝氨酸蛋白酶抑制剂(maspin)]。随后,分析局部复发(LR)、总生存期(OS)和组织学肿瘤消退的预测价值。
与活检相比,治疗后组织中以每平方毫米肿瘤上皮细胞凋亡数定量的凋亡水平更高(P<0.001)。临床T4期肿瘤的活检显示凋亡水平明显高于临床T3期肿瘤(P = 0.020)。放疗最后一天与手术之间的间隔增加时,治疗诱导的凋亡更高(P<0.001,相关系数 = 0.355)。治疗前和治疗后的凋亡、p53、Bcl-2、Bax和Cox-2与LR、OS或肿瘤消退无关。仅maspin治疗前强烈的细胞质染色表明LR风险较高(P = 0.009)。
联合RCT在高凋亡肿瘤中也取得成功,因此与内在凋亡无关。